Global Assessment of Myeloma Response to Chemotherapy
骨髓瘤化疗反应的整体评估
基本信息
- 批准号:9337420
- 负责人:
- 金额:$ 11.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-16 至 2019-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvisory CommitteesAffectAftercareApoptosisApoptoticAwardBasic ScienceBioinformaticsBiologicalBiological AssayBiophysicsBone MarrowBortezomibCaliforniaCell DeathCell LineCell physiologyCellsCellular biologyChemicalsClinicClinicalClinical ManagementClinical ResearchCoculture TechniquesCollaborationsCombined Modality TherapyCommittee MembersCommunitiesComplexDataDevelopmentDiagnostic ProcedureDiseaseDoctor of PhilosophyEvolutionExposure toFutureGlobal ChangeGoalsHematologic NeoplasmsHematopoietic NeoplasmsHomeostasisInduction of ApoptosisInvestigationK-Series Research Career ProgramsKnowledgeLaboratoriesLaboratory ResearchLeadMaintenanceMalignant NeoplasmsMass Spectrum AnalysisMedicineMentorsMentorshipMessenger RNAMethodsMissionModelingMolecular BiologyMolecular ChaperonesMolecular TargetMonitorMultiple MyelomaPathogenesisPathway interactionsPatientsPharmaceutical PreparationsPhosphorylationPhysiciansPlasma CellsPlayPost-Translational Protein ProcessingProcessProductionProteinsProteomicsPublishingRecordsRegimenRegulationResearchResearch PersonnelResearch ProposalsResidenciesResistanceResistance developmentResolutionResourcesRibosomesRoleSan FranciscoScientistSignal TransductionStressStromal CellsSystemSystems BiologyTechnologyTestingTherapeuticTherapeutic EffectTimeTrainingTranscriptTranslational RegulationTranslationsUbiquitinationUnited States National Institutes of HealthUniversitiesWorkbasecancer cellcareercell growth regulationchemotherapycostdeep sequencingdrug mechanisminhibitor/antagonistinsightkillingsknock-downnovelnovel diagnosticsnovel markerphysical modelpublic health relevanceresponseresponse biomarkerribosome profilingsingle moleculesmall hairpin RNAsymposiumtargeted treatmenttenure tracktherapeutic targettherapy resistanttooltreatment responsetumor initiation
项目摘要
DESCRIPTION (provided by applicant): This is a resubmission application for the K08 Mentored Clinical Scientist Research Career Development Award for Dr. Arun Wiita in the Dept. of Laboratory Medicine at the University of California, San Francisco. Dr. Wiita completed his MD/PhD at Columbia University, including highly successful graduate work in single molecule biophysics in the lab of Julio Fernandez, PhD. Since finishing his residency in Laboratory Medicine at UCSF he has been pursuing research in apoptosis in hematologic cancers with Jim Wells, PhD. Despite moving into a very different field, Dr. Wiita has made significant progress on two major projects, one published and the other submitted. His long-term goal is to understand in greater detail how cancer cells evolve and respond to therapies, eventually resulting in new diagnostic tools to assist cancer management. The K08 award will provide Dr. Wiita with the protected time and additional training in bioinformatics, proteomics, and cancer signaling networks critical to his development as a tenure-track physician-scientist primarily devoted to laboratory research. His mentor, Jim Wells, PhD, an expert on therapeutics and cell death, and his co-mentor, Kevin Shannon, MD, an expert on hematologic malignancies, have extremely strong records of mentorship. Additional advisory committee members include Jonathan Weissman, PhD, an expert on systems biology, Al Burlingame, PhD, a pioneer of biological mass spectrometry, and Scott Kogan, MD, a physician-scientist bridging clinical and basic research in Laboratory Medicine. Including coursework and participation in seminars and conferences, Dr. Wiita has drawn on the myriad resources of the UCSF scientific community to promote his career as an independent investigator. The research proposal is centered on using emerging, systems-level technologies to address pressing issues in management of multiple myeloma, an incurable, aggressive hematologic malignancy. In Aim 1 Dr. Wiita has begun to develop a unique pipeline combining mRNA deep sequencing, ribosome profiling, and quantitative proteomics to monitor bortezomib-induced cell death in myeloma cells. These studies have already revealed extensive biological insight into translational dynamics after bortezomib exposure. Here he will expand these studies with new proteomic and analysis methods to monitor the role of post-translational modifications and cellular signaling. In Aim 2 Dr. Wiita will use the first-of-its-kind data obtained in this pipeline to develop a new quantitatie model of protein translation and translational regulation. These processes are key determinants of cellular homeostasis and regulation and also play an important role in myeloma pathogenesis. In Aim 3 Dr. Wiita will use cell and molecular biology approaches to elucidate resistance and response markers as well as combination therapeutic targets in myeloma, driven by hypotheses based on systems-level data. These studies are deeply related to the missions of the NIH and NCI as they will greatly expand our understanding of therapeutic effects in myeloma and, in the future, potentially any malignancy.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Arun P. Wiita其他文献
Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia
针对 CLL-1 的细胞免疫疗法用于幼年型粒单核细胞白血病
- DOI:
10.1038/s41467-025-59040-6 - 发表时间:
2025-04-23 - 期刊:
- 影响因子:15.700
- 作者:
Juwita Werner;Alex G. Lee;Chujing Zhang;Sydney Abelson;Sherin Xirenayi;Jose Rivera;Khadija Yousuf;Hanna Shin;Bonell Patiño-Escobar;Stefanie Bachl;Kamal Mandal;Abhilash Barpanda;Emilio Ramos;Adila Izgutdina;Sibapriya Chaudhuri;William C. Temple;Shubhmita Bhatnagar;Jackson K. Dardis;Julia Meyer;Carolina Morales;Soheil Meshinchi;Mignon L. Loh;Benjamin Braun;Sarah K. Tasian;Arun P. Wiita;Elliot Stieglitz - 通讯作者:
Elliot Stieglitz
Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression
膀胱癌变异体具有侵袭性特征,包括 CA125+细胞状态和可靶向的 TM4SF1 表达
- DOI:
10.1038/s41467-025-59888-8 - 发表时间:
2025-06-17 - 期刊:
- 影响因子:15.700
- 作者:
Heiko Yang;Hanbing Song;Elizabeth Yip;Timothy Gilpatrick;Kevin Chang;Paul Allegakoen;Kevin L. Lu;Keliana Hui;Julia H. Pham;Corynn Kasap;Vipul Kumar;Janae Gayle;Bradley A. Stohr;Chien-Kuang Cornelia Ding;Arun P. Wiita;Maxwell V. Meng;Jonathan Chou;Sima P. Porten;Franklin W. Huang - 通讯作者:
Franklin W. Huang
Time-resolved proteomics vs. ribosome profiling reveals translation dynamics under stress
时间分辨蛋白质组学与核糖体分析揭示了压力下的翻译动态
- DOI:
10.1101/087486 - 发表时间:
2016 - 期刊:
- 影响因子:0
- 作者:
Tzu;Hector H. Huang;Diamond Wheeler;James A. Wells;Yun S. Song;Arun P. Wiita - 通讯作者:
Arun P. Wiita
Tumour-wide RNA splicing aberrations generate actionable public neoantigens
肿瘤范围的 RNA 剪接异常产生可操作的公共新抗原
- DOI:
10.1038/s41586-024-08552-0 - 发表时间:
2025-02-19 - 期刊:
- 影响因子:48.500
- 作者:
Darwin W. Kwok;Nicholas O. Stevers;Iñaki Etxeberria;Takahide Nejo;Maggie Colton Cove;Lee H. Chen;Jangham Jung;Kaori Okada;Senthilnath Lakshmanachetty;Marco Gallus;Abhilash Barpanda;Chibo Hong;Gary K. L. Chan;Jerry Liu;Samuel H. Wu;Emilio Ramos;Akane Yamamichi;Payal B. Watchmaker;Hirokazu Ogino;Atsuro Saijo;Aidan Du;Nadia R. Grishanina;James Woo;Aaron Diaz;Shawn L. Hervey-Jumper;Susan M. Chang;Joanna J. Phillips;Arun P. Wiita;Christopher A. Klebanoff;Joseph F. Costello;Hideho Okada - 通讯作者:
Hideho Okada
DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma
DNA 甲基转移酶抑制剂上调多发性骨髓瘤中 CD38 蛋白表达并增强达雷木单抗疗效
- DOI:
10.1038/s41375-019-0587-5 - 发表时间:
2019-10-08 - 期刊:
- 影响因子:13.400
- 作者:
Priya Choudhry;Margarette C. Mariano;Huimin Geng;Thomas G. Martin;Jeffrey L. Wolf;Sandy W. Wong;Nina Shah;Arun P. Wiita - 通讯作者:
Arun P. Wiita
Arun P. Wiita的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Arun P. Wiita', 18)}}的其他基金
Structural Surfaceomics: A Strategy for Immunotherapy Target Discovery
结构表面组学:免疫治疗靶点发现的策略
- 批准号:
10290239 - 财政年份:2021
- 资助金额:
$ 11.27万 - 项目类别:
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy
利用骨髓瘤蛋白质组重塑来延长蛋白酶体抑制剂的功效
- 批准号:
10308238 - 财政年份:2021
- 资助金额:
$ 11.27万 - 项目类别:
ClinTAD: A Tool for Improving Clinical CNV Interpretation
ClinTAD:改善临床 CNV 解读的工具
- 批准号:
10461112 - 财政年份:2021
- 资助金额:
$ 11.27万 - 项目类别:
Structural Surfaceomics: A Strategy for Immunotherapy Target Discovery
结构表面组学:免疫治疗靶点发现的策略
- 批准号:
10434121 - 财政年份:2021
- 资助金额:
$ 11.27万 - 项目类别:
ClinTAD: A Tool for Improving Clinical CNV Interpretation
ClinTAD:改善临床 CNV 解读的工具
- 批准号:
10286951 - 财政年份:2021
- 资助金额:
$ 11.27万 - 项目类别:
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy
利用骨髓瘤蛋白质组重塑来延长蛋白酶体抑制剂的功效
- 批准号:
10341162 - 财政年份:2018
- 资助金额:
$ 11.27万 - 项目类别:
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy
利用骨髓瘤蛋白质组重塑来延长蛋白酶体抑制剂的功效
- 批准号:
10524110 - 财政年份:2018
- 资助金额:
$ 11.27万 - 项目类别:
In vivo monitoring of oxidative protein folding through time-resolved quantitative mass spectrometry
通过时间分辨定量质谱法体内监测氧化蛋白折叠
- 批准号:
9167306 - 财政年份:2016
- 资助金额:
$ 11.27万 - 项目类别:
Global Assessment of Myeloma Response to Chemotherapy
骨髓瘤化疗反应的整体评估
- 批准号:
8819976 - 财政年份:2014
- 资助金额:
$ 11.27万 - 项目类别:
Global Assessment of Myeloma Response to Chemotherapy
骨髓瘤化疗反应的整体评估
- 批准号:
8928081 - 财政年份:2014
- 资助金额:
$ 11.27万 - 项目类别:
相似海外基金
Toward a Political Theory of Bioethics: Participation, Representation, and Deliberation on Federal Bioethics Advisory Committees
迈向生命伦理学的政治理论:联邦生命伦理学咨询委员会的参与、代表和审议
- 批准号:
0451289 - 财政年份:2005
- 资助金额:
$ 11.27万 - 项目类别:
Standard Grant